RhumbLine Advisers’s Can-Fite BioPharma CANF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $60.5K | Buy |
57,582
+19,314
| +50% | +$20.3K | ﹤0.01% | 3642 |
|
|
2025
Q1 | $56.6K | Buy |
38,268
+11,388
| +42% | +$16.9K | ﹤0.01% | 3543 |
|
|
2024
Q4 | $43.7K | Buy |
26,880
+9,935
| +59% | +$16.1K | ﹤0.01% | 3676 |
|
|
2024
Q3 | $34.1K | Buy |
16,945
+1,547
| +10% | +$3.11K | ﹤0.01% | 3745 |
|
|
2024
Q2 | $39.7K | Sell |
15,398
-3,084
| -17% | -$7.96K | ﹤0.01% | 3742 |
|
|
2024
Q1 | $41K | Hold |
18,482
| – | – | ﹤0.01% | 3671 |
|
|
2023
Q4 | $40.7K | Buy |
18,482
+560
| +3% | +$1.23K | ﹤0.01% | 3667 |
|
|
2023
Q3 | $47.5K | Buy |
17,922
+820
| +5% | +$2.17K | ﹤0.01% | 3652 |
|
|
2023
Q2 | $52.5K | Buy |
+17,102
| New | +$52.5K | ﹤0.01% | 3671 |
|